肺动脉高压治疗领域迎突破:新华制药创新药获批临床,远大医药新规格药物上市

制药网
Sep 26

肺动脉高压(PAH)作为一种罕见却危害极大的心血管疾病,正困扰着全球约 1% 的人口。这一疾病不仅严重影响患者的生活质量,更对生命健康构成重大威胁。近期,PAH药物领域传来多个好消息,涉及新华制药、远大医药等。其中新华制药9月25日公告称,与中南大学联合研发的I类创新药LXH-1211取得药物临床试验批准通知书,获准针对肺动脉高压开展临床试验。而远大医药近日公告称,公司曲前列尼尔注射液的新规格(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10